India, Sept. 23 -- Johnson & Johnson (JNJ) reported new model-based analyses from its Phase 3 MajesTEC-3 study suggesting that the combination of TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) may help improve long-term survival outcomes for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. While treatment options have improved in recent years, many patients eventually experience disease relapse, creating a need for therapies that can provide longer-lasting disease control.
The findings were based on additional analyses of data from the Phase 3 MajesTEC-3...